MX386543B - Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo. - Google Patents

Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo.

Info

Publication number
MX386543B
MX386543B MX2017011480A MX2017011480A MX386543B MX 386543 B MX386543 B MX 386543B MX 2017011480 A MX2017011480 A MX 2017011480A MX 2017011480 A MX2017011480 A MX 2017011480A MX 386543 B MX386543 B MX 386543B
Authority
MX
Mexico
Prior art keywords
antigen
binding fragment
medical use
sclerostin antibody
antibody
Prior art date
Application number
MX2017011480A
Other languages
English (en)
Other versions
MX2017011480A (es
Inventor
Dongbing Cui
Haoying Zhang
Jiajian Liu
Lianshan Zhang
Ling Zhang
Weikang Tao
Yayuan Fu
Yifang Wang
Zhen Zhang
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017011480A publication Critical patent/MX2017011480A/es
Publication of MX386543B publication Critical patent/MX386543B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un anticuerpo humanizado y un anticuerpo quimérico que se une específicamente a la esclerostina humana. Los anticuerpos pueden usarse para tratar enfermedades relacionadas con el metabolismo óseo humano tales como la osteoporosis (OP).
MX2017011480A 2015-03-13 2016-02-16 Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo. MX386543B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510112924 2015-03-13
PCT/CN2016/073857 WO2016145961A1 (zh) 2015-03-13 2016-02-16 抗硬骨素抗体、其抗原结合片段及其医药用途

Publications (2)

Publication Number Publication Date
MX2017011480A MX2017011480A (es) 2018-04-24
MX386543B true MX386543B (es) 2025-03-18

Family

ID=56919707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011480A MX386543B (es) 2015-03-13 2016-02-16 Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo.

Country Status (19)

Country Link
US (1) US10449250B2 (es)
EP (2) EP3782641A1 (es)
JP (1) JP6755513B2 (es)
KR (1) KR102584953B1 (es)
CN (2) CN106661104B (es)
AU (1) AU2016232897B2 (es)
CA (1) CA2978976C (es)
DK (1) DK3269735T3 (es)
ES (1) ES2835923T3 (es)
HR (1) HRP20201862T1 (es)
HU (1) HUE052528T2 (es)
LT (1) LT3269735T (es)
MX (1) MX386543B (es)
PT (1) PT3269735T (es)
RS (1) RS61158B1 (es)
RU (1) RU2716101C2 (es)
SI (1) SI3269735T1 (es)
TW (2) TWI790617B (es)
WO (1) WO2016145961A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200034748A (ko) * 2017-07-27 2020-03-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Sost 항체 약학적 조성물 및 그의 용도
CN108101984B (zh) * 2017-12-18 2019-10-15 中国人民解放军总医院 骨硬化蛋白单链抗体的制备方法和用途
CN111712573B (zh) 2018-02-12 2023-10-20 安沛治疗有限公司 针对骨硬化蛋白的适体及其用途
CN113913463B (zh) * 2021-09-19 2023-08-18 郭保生 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用
EP4434517A4 (en) 2021-11-30 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-sost antibody pharmaceutical composition and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
NZ578635A (en) * 2006-12-26 2012-03-30 Ct De Inmunolgia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
EP2131860B1 (en) * 2007-03-20 2013-12-18 Eli Lilly & Company Anti-sclerostin antibodies
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008338464A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
KR20190120401A (ko) * 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas

Also Published As

Publication number Publication date
TW201632550A (zh) 2016-09-16
TWI730954B (zh) 2021-06-21
SI3269735T1 (sl) 2020-12-31
RU2017132924A (ru) 2019-04-15
RU2017132924A3 (es) 2019-06-03
TWI790617B (zh) 2023-01-21
HUE052528T2 (hu) 2021-05-28
LT3269735T (lt) 2020-12-28
AU2016232897B2 (en) 2021-05-13
KR102584953B1 (ko) 2023-10-04
CN111196849A (zh) 2020-05-26
EP3269735A4 (en) 2018-09-19
DK3269735T3 (da) 2020-12-14
US20180099046A1 (en) 2018-04-12
CN106661104B (zh) 2019-04-02
EP3269735A1 (en) 2018-01-17
CA2978976C (en) 2024-05-14
JP6755513B2 (ja) 2020-09-16
EP3269735B1 (en) 2020-11-04
US10449250B2 (en) 2019-10-22
PT3269735T (pt) 2020-12-04
EP3782641A1 (en) 2021-02-24
BR112017019075A2 (pt) 2018-04-17
KR20170126971A (ko) 2017-11-20
ES2835923T3 (es) 2021-06-23
HRP20201862T1 (hr) 2021-01-22
AU2016232897A1 (en) 2017-10-05
RS61158B1 (sr) 2021-01-29
RU2716101C2 (ru) 2020-03-05
TW202134271A (zh) 2021-09-16
JP2018509147A (ja) 2018-04-05
CN106661104A (zh) 2017-05-10
CA2978976A1 (en) 2016-09-22
MX2017011480A (es) 2018-04-24
CN111196849B (zh) 2021-12-21
WO2016145961A1 (zh) 2016-09-22

Similar Documents

Publication Publication Date Title
ES3063317T3 (en) Humanized or chimeric cd3 antibodies
CL2025002241A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
PH12020552178A1 (en) Anti-il36r antibodies
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
MX2017014188A (es) Anticuerpos anti-ox40 y metodos para su uso.
PE20180315A1 (es) Anticuerpos para cd40
PH12016501366A1 (en) Novel anti-baff antibodies
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX2016015614A (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
ES3052034T3 (en) Humanized or chimeric cd3 antibodies
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
MX2017000205A (es) Anticuerpos anti-tau humanizados.
MX2018005061A (es) Compuestos de interacción con glicanos y métodos de uso.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
MX392703B (es) Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada.
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2017001686A (es) Anticuerpos anti-ceramida.
MX2017011480A (es) Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo.
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.